it's not disrupted as much as margin.
they already sell a bucket full of product. In a market that is price sensitive. So by adding a 2.5%-5% royalty to cost, what would you need to increase your price to make the same profit. This could mean a 10%+ increase.
Then you ask yourself would it bring in more volume than already there.
So their other option was to isolate the cost in a wand type product. They made a very nice profit from the tech and did not harm their bottom line.
Question for them is how many wands can a person want. Simply cannot keep offering a new version so the well runs dry.
Handing it back allows for PP to do something with it and integrate it into caps like it should have been.
If they come up with something interesting PG will be come knocking.
The real question is what are the binding terms to this. No royalty payable (that would have been a laugh if they started making more of us from actually selling a product considering they got it for free).
we will find out one day when they sell something.
- Forums
- ASX - By Stock
- WFL
- Ann: P&G Grants Non Exclusive License
Ann: P&G Grants Non Exclusive License, page-29
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online